InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Browse the detailed record of transactions filed by MURPHY ANDREW J, Vice-Président Exécutif Recherche. Director active across 1 companies, notably Regeneron Pharmaceuticals, INC.. In total, 8 filings have been recorded. The latest transaction was filed on 16 May 2022 — Levée d'options. Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations8 total
€2m10,000 shares@ €171.59760.0023% mcap41.7% of flow
Common Stock
SEC:0001883850-22-000046:0·
€2m10,000 shares@ €157.61470.0022% mcap38.3% of flow
Common Stock
SEC:0001708138-22-000014:0·
€410,017697 shares@ €588.25980.0006% mcap100.0% of flow
Common Stock
SEC:0001708138-21-000105·
€410,017697 shares@ €588.25980.0006% mcap10.0% of flow
Common Stock
SEC:0001708138-21-000105:0·
03,462 shares0
Common Stock
SEC:0001708138-21-000098·
03,462 shares0
Common Stock
SEC:0001708138-21-000098:0·
01,645 shares0
Common Stock
SEC:0001708138-21-000086·
01,645 shares0
Common Stock
SEC:0001708138-21-000086:0·
8 of 8 declarations
About MURPHY ANDREW J
Andrew J. Murphy is Executive Vice President of Research at REGENERON PHARMACEUTICALS, INC. He is responsible for leading the company's research initiatives, contributing to innovation in the pharmaceutical sector.
